US Edition
GLP-1 implant NPM-115 meets primary endpoint
Summary by bariatricnews.net
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
GLP-1 implant NPM-115 meets primary endpoint
Vivani Medical has revealed that results from the LIBERATE-1 clinical study, a Phase 1 study of the exenatide GLP-1 implant NPM-115 representing the first-in-human test of NanoPortal implant technology, has shown the it successfully met its primary objectives, which were to evaluate the NPM-115 implant’s safety and tolerability profile and to characterise the pharmacokinetic (PK) profile of the implant over a nine-week duration.Throughout the st…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium